Join the Acute Lymphoblastic Leukemia group to help and get support from people like you.
Acute Lymphoblastic Leukemia News (Page 2)
FDA Approves Besponsa (inotuzumab ozogamicin) for Relapsed or Refractory Acute Lymphoblastic Leukemia
August 17, 2017 – The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic...
FDA Grants Full Approval for Blincyto (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children
THOUSAND OAKS, Calif., July 11, 2017 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...
FDA Approves Xatmep (methotrexate) Oral Solution
Denver, April 26, 2017 — Silvergate Pharmaceuticals, Inc. leaders in the development and commercialization of innovative and safe medicines for children, today announced that the United States Food a...
FDA Approves Blincyto (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
THOUSAND OAKS, Calif., Sept. 1, 2016 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...
Jazz Pharmaceuticals Receives FDA Approval For Intravenous Administration Of Erwinaze
DUBLIN, Dec. 19, 2014 /PRNewswire/ – Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (FDA) approved the intravenous administration of Erwinaze (asparaginase...
FDA Approves Blincyto (blinatumomab) for Precursor B-Cell Acute Lymphoblastic Leukemia
December 3, 2014 – The U.S. Food and Drug Administration today approved Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia...
FDA Approves Purixan (mercaptopurine) Oral Suspension
April 29, 2014 – On April 28, 2014, the U. S. Food and Drug Administration approved an oral suspension of mercaptopurine (Purixan, NOVA Laboratories Limited). Mercaptopurine is a 20 mg/ml oral...
FDA Approves Gleevec for Children with Acute Lymphoblastic Leukemia
January 25, 2013 – The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute...
FDA Approves Iclusig to Treat Two Rare Types of Leukemia
December 14, 2012 - The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute...
FDA Approves Marqibo for Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia
August 9, 2012 – The U.S. Food and Drug Administration today approved Marqibo (vincristine sulfate liposome injection) to treat adults with a rare type of leukemia called Philadelphia chromosome...
FDA Approves Erwinaze to Treat Acute Lymphoblastic Leukemia
November 18, 2011 – The U.S. Food and Drug Administration today approved Erwinaze (asparaginase Erwinia chrysanthemi) to treat patients with acute lymphoblastic leukemia (ALL), who have developed an...
FDA approves additional medical indication for Sprycel
SILVER SPRING, Md., Oct. 28 - The U.S. Food and Drug Administration today approved a new indication for Sprycel (dasatinib) for the treatment of a rare blood cancer when it is first diagnosed. The...
Ask a question
To post your own question to this support group, sign in or create an account.